<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F92E872F-4E47-4ADB-BA08-E5C4987A14A1"><gtr:id>F92E872F-4E47-4ADB-BA08-E5C4987A14A1</gtr:id><gtr:firstName>Adeeba</gtr:firstName><gtr:surname>Ahmed</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6638"><gtr:id>EC794DEA-226F-4B81-BA90-F39EDE2CD383</gtr:id><gtr:title>The role of 11 Beta Hydroxysteroid Dehydrogenase Type 1 and Hexose-6-Phosphate Dehydrogenase in the metabolic syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6638</gtr:grantReference><gtr:abstractText>The link between central obesity and sugar diabetes is well established and is recognised as an increasingly common health hazard. We have come up with a mechanism that might explain this link - an enzyme present in liver and fat that can generate a hormone called cortisol that directly predisposes to obesity and diabetes. This study will address the role of this enzyme and additional regulating enzymes specifically in the liver and their contribution to the development and progression of diabetes. It will directly look at the effect of cortisol upon glucose production from liver cells grown in the laboratory and the effect that our candidate enzymes have on this process. Additional clinical studies will use novel methods to measure glucose output from the liver in patients with obesity, sugar diabetes and fatty liver and to compare this with normal volunteers. It will provide the key research basis for the development of a new treatment for obesity-related diabetes - ?11 HSD1 inhibitors?. This would potentially have a huge impact in the management of diabetes and in particular delay or prevent the progression to treatment with insulin.</gtr:abstractText><gtr:technicalSummary>Background, Aims and Relevance: The constellation of central obesity, diabetes mellitus, hepatic steatosis, hyperlipidaemia and hypertension - so-called metabolic syndrome - represents a major global health hazard and one that directly contributes to premature mortality from cardiovascular disease. Although the underlying mechanisms remain uncertain, we have proposed a novel candidate, 11&amp;szlig;-hydroxysteroid dehydrogenase type 1 (11&amp;szlig;-HSD1), that might explain disease pathogenesis, or importantly offer a new therapeutic target. 11 -HSD1 converts inactive cortisone to active cortisol in key glucocorticoid target tissues including adipose tissue and liver. In human liver it facilitates hepatic gluconeogenesis through stimulation of glucose-6-phosphate dehydrogenase (G6PD) and phosphoenolpyruvate carboxykinase (PEPCK) activities. 11&amp;szlig;-HSD1 inhibitors have shown a dramatic beneficial effect upon insulin sensitivity largely mediated through a reduction in hepatic glucose output.
Purified 11&amp;szlig;-HSD1 acts, similar to its renal homologue (11&amp;szlig;-HSD2) as a highly efficient dehydrogenase inactivating cortisol to cortisone. The directionality of the enzymes appears intricately linked to an NADPH regeneration system influenced by the cytosolic enzyme - hexose-6-phosphate dehydrogenase (H6PDH). 
On this background, the aim of this study is to explore the impact of H6PDH upon hepatic glucose output, specifically through its interaction with 11&amp;szlig;-HSD1. In vitro studies will utilise mouse tissues to assess the impact of cortisone on hepatic gluconeogenesis with and without the presence selective 11&amp;szlig;-HSD1 inhibitors and as well as studies on mice deficient in H6PDH. Clinical studies will be undertaken on patients with established mutations in the HSD11B1 and H6PDH genes (cortisone reductase deficiency) and in patients with obesity and hepatic steatosis +/- glucose intolerance and will comprise a deuterated water method to determine hepatic gluconeogenesis, 24hr urinary steroid profilertisone day curves to assess hepatic 11 -HSD1 activity, and, where appropriate quantification of 11 -HSD1 and H6PDH expression from liver biopsy material.
The above studies will form an excellent platform for future phase II studies of selective 11&amp;szlig;-HSD1 inhibitors in man and will further our understanding of the role of hepatic 11 -HSD1 and H6PDH in patients with the metabolic syndrome.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>157179</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6BFC3778-3FBC-4AC5-BAB7-FC00C2C7B4B3</gtr:id><gtr:title>A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>LiSsNze9v9W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>903BE72F-5807-49BE-8E61-D536A7BABB4D</gtr:id><gtr:title>Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>BF42EEE37A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BEBCCE5-5764-444F-A1C8-6EB456F184BA</gtr:id><gtr:title>11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/013fb76c9f158ebf6e606b94ae6c6a63"><gtr:id>013fb76c9f158ebf6e606b94ae6c6a63</gtr:id><gtr:otherNames>Walker EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>49DFEF92E22</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6638</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>